1. Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings,
77(4), 371–383. doi:
10.4065/77.4.371
.
2. Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology,
61(2), 102–109. doi:
10.1016/j.jclinepi.2007.03.012
.
3. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials,
10(4), 407–415. doi:
10.1016/0197-2456(89)90005-6
.
4. Wells, G., Li, T., Maxwell, L., MacLean, R., & Tugwell, P. (2007). Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology,
34(2), 280–289.
5. Bellamy, N., Anastassiades, T. P., Buchanan, W. W., Davis, P., Lee, P., McCain, G. A., et al. (1991). Rheumatoid arthritis antirheumatic drug trials. III. Setting the delta for clinical trials of antirheumatic drugs—Results of a consensus development (Delphi) exercise. Journal of Rheumatology,
18(12), 1908–1915.